Clinical Trials Browser

PRETEXT I Hepatoblastoma

Colonic Neoplasms

Colorectal Neoplasms

Urinary Bladder Neoplasms

Colorectal Neoplasms

Colonic Neoplasms, Rectal Neoplasms

Pathologic Complete Response

Adenocarcinoma, Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Colorectal Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Stomach Neoplasms

Metastatic Adenocarcinoma of the Pancreas

HER2-positive Gastric Cancer

Colorectal Neoplasms

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Adenocarcinoma Of Esophagus

Colorectal Adenocarcinoma

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Colorectal Adenocarcinoma

Rectal Neoplasms

Colorectal Neoplasms

Adenocarcinoma Of Esophagus

Colorectal Neoplasms

Squamous Cell Carcinoma of Head and Neck

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

Resectable Colon Cancer

Adenocarcinoma Of Esophagus, Adenocarcinoma, Esophageal Neoplasms, Stomach Neoplasms

Pancreatic Intraductal Neoplasms

Pancreatic Neoplasms

Clinical Trials

Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

MOUNTAINEER-03

KANDLELIT-012

MEND-IT II

LUCERNA

MK-3475-C66

KEYNOTE-585

NAPOLI 3

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

TRIBE-C

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

STAR-221

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

SOLARIS

FOBEAR

HARMONi-GI3

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

RePaIr-HN

HERIZON-GEA-01

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations